For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
COVID in the community – a policy black spot
Wednesday 24 November 2021, 03:40 AM

[Ronstik on iStock]
This is how our journalists covered the fits-and-starts evolution of a system for COVID-19 care in the community – while patients and whānau faced all kinds of problems trying to isolate at home. We reveal how difficult it has been to get a clear picture of what is expected of general practice, as the pandemic exposes poor or non-existent relationships across the health sector
The makings of a plan, 13 October
Health minister Andrew Little gives a briefing at Parliament on COVID care in the community. A worst-case scenario is raised in latest m, Andrew Little (cropped), The plan will swing into action once vaccination levels are considered high enough to enable a relaxation of lockdown restrictions – Andrew Little
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
Related Articles
Print Archive
How to Treat
Wednesday 28 May 2025, 12:50 AM
Latest news
04/06/2025
Events
Latest issue
Most popular
03/06/2025
That's interesting
Gallery
National Rural Health Conference 2025 Gallery